#France #Montpellier #Tsingke Biotech #CLDN18.2 #AIS 2026

Tsingke's Groundbreaking Presentation at AIS 2026

On July 8, 2026, at the prestigious Antibody Industrial Symposium (AIS) held in Montpellier, France, Tsingke Biotech proudly shared their latest innovations in AI-assisted therapeutic antibody discovery. This annual conference is recognized as one of Europe's vital platforms focusing on advancements in therapeutic antibodies and biotherapeutics. Tsingke's booth, #44, showcased their cutting-edge antibody development platform, underscoring their commitment to revolutionizing therapeutic solutions.

AI-Powered Antibody Discovery

During the symposium, Tsingke revealed their novel methodology for discovering mono-specific CLAUDIN 18.2 (CLDN18.2) antibodies. These antibodies aim to target the increasing concern of gastric cancer and other solid tumors affecting patients worldwide. The scientific presentation detailed how artificial intelligence not only enhances sequencing analysis but also streamlines a unique screening approach. This innovation significantly improves target specificity while minimizing cross-reactivity with the closely related protein CLDN18.1, a prevalent hurdle in CLDN18.2 antibody creation.

The outcomes from this AI-driven approach have produced candidate antibodies that exhibit remarkable specificity. This emphasizes the profound impact that integrating computational methods with experimental validation can have on accelerating therapeutic antibody and antibody-drug conjugate development processes. Following this, the resulting candidates demonstrate high levels of developability which is crucial in therapeutic antibody applications.

Comprehensive Antibody Development Capabilities

Beyond the scientific discourse, Tsingke showcased their robust and integrated antibody development platform. Key features of this platform include:

• - Antibody Discovery: Utilizing hybridoma, single B-cell, and phage display technologies, Tsingke identifies high-affinity, highly specific antibodies.

• - Antibody Engineering: Tsingke specializes in antibody humanization, affinity maturation, and constructing synthetic antibody libraries, which expedite the optimization of therapeutic antibodies.

• - Protein Expression: With support from an array of six expression systems, Tsingke's rapid gene-to-protein workflow encompasses the production of monoclonal antibodies, antibody-drug conjugates (ADCs), antibody-Oligonucleotide Conjugates (AOCs), and in vitro diagnostics (IVD).

Chuanting Tan, Senior R&D Engineer at Tsingke, noted, "The AIS 2026 platform stands as a beneficial environment for sharing our GS-enabled advancements in antibody discovery. As the landscape of therapeutic antibody development evolves further into complexity, the merger of computational techniques with hands-on validation is paramount. This enables researchers to pinpoint and optimize promising candidates more efficiently."

Future Expectations

Looking ahead, Tsingke plans to amplify its offering by expanding its AI-enabled discovery platform and integrated biologics capabilities. By doing so, they aim to assist researchers in accelerating their projects from the critical stages of original target discovery through to the final stages of protein expression and characterization.

About Tsingke

Established as a pioneer in synthetic biology, Tsingke Biotech's mission is to construct “the world’s greatest gene factory.” By integrating proprietary reagents, consumables, and synthesis equipment with groundbreaking AI-driven molecular manufacturing technologies, Tsingke ensures the provision of efficient, high-quality Tsynth® gene synthesis services. Their innovations support various sectors, ranging from biopharmaceuticals to agriculture, food production, and environmental sciences.

For ongoing news and updates about Tsingke Biotech, stay connected through LinkedIn.